CoChat
Sign Up
Cited by 277RNA Interference and Gene DeliveryCRISPR and Genetic EngineeringNanoparticle-Based Drug Delivery

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Nonviral gene editing via CRISPR/Cas9 delivery by membrane-disruptive and endosomolytic helical polypeptide

Open access
Wang, Hong-Xia, Song, Ziyuan, Lao, Yeh-Hsing, Xu, Xin, Gong, Jing, Cheng, Du, Chakraborty, Syandan, Park, Ji Sun, Li, Mingqiang, Huang, Dantong, Yin, Lichen, Cheng, Jianjun, Leong, Kam W.·2018·Proceedings of the National Academy of Sciences
DOI 10.1073/pnas.1712963115PMC PMC5948953
Open this paper in CoChat — free account

Abstract

Effective and safe delivery of the CRISPR/Cas9 gene-editing elements remains a challenge. Here we report the development of PEGylated nanoparticles (named P-HNPs) based on the cationic α-helical polypeptide poly(γ-4-((2-(piperidin-1-yl)ethyl)aminomethyl)benzyl-l-glutamate) for the delivery of Cas9 expression plasmid and sgRNA to various cell types and gene-editing scenarios. The cell-penetrating α-helical polypeptide enhanced cellular uptake and promoted escape of pCas9 and/or sgRNA from the endosome and transport into the nucleus. The colloidally stable P-HNPs achieved a Cas9 transfection efficiency up to 60% and sgRNA uptake efficiency of 67.4%, representing an improvement over existing polycation-based gene delivery systems. After performing single or multiplex gene editing with an efficiency up to 47.3% in vitro, we demonstrated that P-HNPs delivering Cas9 plasmid/sgRNA targeting the polo-like kinase 1 (Plk1) gene achieved 35% gene deletion in HeLa tumor tissue to reduce the Plk1 protein level by 66.7%, thereby suppressing the tumor growth by >71% and prolonging the animal survival rate to 60% within 60 days. Capable of delivering Cas9 plasmids to various cell types to achieve multiplex gene knock-out, gene knock-in, and gene activation in vitro and in vivo, the P-HNP system offers a versatile gene-editing platform for biological research and therapeutic applications.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.1712963115

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1. Schematic illustration showing the formation of P-HNPs and the intracellular activity of Cas9 expression plasmid/sgRNA in performing genome editing or gene activation.
Fig. 1. Schematic illustration showing the formation of P-HNPs and the intracellular activity of Cas9 expression plasmid/sgRNA in performing genome editing or gene activation.CC BY-NC-ND · PubMed Central
Fig. 2. Transfection of Cas9-GFP plasmid px458 in a variety of cells. The HNPs were formed by PPABLG/px458 at the wt/wt ratio of 30:1. The P-HNPs were formed by PPABLG/px458/PEG2k-T40 at the wt/wt/wt ratio of 30:1:1. Free, treatment with naked plasmids; UT, untreated group.
Fig. 2. Transfection of Cas9-GFP plasmid px458 in a variety of cells. The HNPs were formed by PPABLG/px458 at the wt/wt ratio of 30:1. The P-HNPs were formed by PPABLG/px458/PEG2k-T40 at the wt/wt/wt ratio of 30:1:1. Free, treatment with naked plasmids; UT, untreated group.CC BY-NC-ND · PubMed Central
Fig. 3. In vitro gene disruption. (A) EGFP disruption assay of Cas9 expression plasmid and sgRNA expression plasmid delivery by HNPs or P-HNPs in U2OS.EGFP reporter cells. The ratios in the figure are weight ratios for Cas9 expression plasmid:sgRNA expression plasmid. (B and C) EGFP disruption assay of Cas9 expression plasmid and in vitro-synthesized sgRNA delivery in U2OS.EGFP reporter cells. Short dash under the bars in B indicates the group treated by only Cas9 expression plasmids. (D–F) GCD assay of indels in the EGFP gene in U2OS.EGFP cells (D), the AAVS1 gene in HEK293T cells (E), and the HPRT1 gene in HEK293T cells (F). “Multi” is the group treated by Cas9 expression plasmid delivery and subsequent codelivery of AAVS1- and HPRT1-targeting sgRNAs. Arrows indicate the cutting products. Free, treatment with naked nucleic acids; UT, untreated group.
Fig. 3. In vitro gene disruption. (A) EGFP disruption assay of Cas9 expression plasmid and sgRNA expression plasmid delivery by HNPs or P-HNPs in U2OS.EGFP reporter cells. The ratios in the figure are weight ratios for Cas9 expression plasmid:sgRNA expression plasmid. (B and C) EGFP disruption assay of Cas9 expression plasmid and in vitro-synthesized sgRNA delivery in U2OS.EGFP reporter cells. Short dash under the bars in B indicates the group treated by only Cas9 expression plasmids. (D–F) GCD assay of indels in the EGFP gene in U2OS.EGFP cells (D), the AAVS1 gene in HEK293T cells (E), and the HPRT1 gene in HEK293T cells (F). “Multi” is the group treated by Cas9 expression plasmid delivery and subsequent codelivery of AAVS1- and HPRT1-targeting sgRNAs. Arrows indicate the cutting products. Free, treatment with naked nucleic acids; UT, untreated group.CC BY-NC-ND · PubMed Central
Fig. 4. In vitro gene insertion and gene activation. (A) Donor architecture for HDR of the AAVS1 gene. The arrows show the locations of PCR primers for detecting successful HDR events. (B) PCR assay to detect HDR events 3 d after transfection. (C) Microscopic images of two GFP+ clones after treatment by P-HNPs loaded with Cas9 expression plasmids and the synthetic sgRNAs and HDR donor after selection with puromycin for 2 wk. (Scale bar, 100 μm.) (D) Sanger sequencing of the HDR events in the selected GFP+ clones in C. (E) The transfection efficiency of P-HNPs for pMax-VP64dCas9-BFPVP64 plasmid by detecting the BFP-positive cells. (F) The qRT-PCR evaluation of relative Myod1 mRNA level to detect the Myod1 activation. The results were shown as the ratio relative to the mRNA expression of the untreated cells. Free, treatment with naked nucleic acids; UT, untreated group.
Fig. 4. In vitro gene insertion and gene activation. (A) Donor architecture for HDR of the AAVS1 gene. The arrows show the locations of PCR primers for detecting successful HDR events. (B) PCR assay to detect HDR events 3 d after transfection. (C) Microscopic images of two GFP+ clones after treatment by P-HNPs loaded with Cas9 expression plasmids and the synthetic sgRNAs and HDR donor after selection with puromycin for 2 wk. (Scale bar, 100 μm.) (D) Sanger sequencing of the HDR events in the selected GFP+ clones in C. (E) The transfection efficiency of P-HNPs for pMax-VP64dCas9-BFPVP64 plasmid by detecting the BFP-positive cells. (F) The qRT-PCR evaluation of relative Myod1 mRNA level to detect the Myod1 activation. The results were shown as the ratio relative to the mRNA expression of the untreated cells. Free, treatment with naked nucleic acids; UT, untreated group.CC BY-NC-ND · PubMed Central
Fig. 5. In vivo gene disruption and tumor growth suppression. (A) Indels of the Plk1 gene in HeLa cells treated with P-HNPs containing px165 only (P-HNPPCas9) or P-HNPs containing px165 and Plk1-targeting sgRNAs (P-HNPPCas9+sgPlk1). (B) Viability of HeLa cells at 72 h after transfection with P-HNPPCas9 or P-HNPPCas9+sgPlk1. Free, cells treated with free px165 and free Plk1-targeting sgRNAs; UT, untreated cells. (C) The inhibition of tumor growth in HeLa xenograft tumor-bearing mice after intratumoral injection of P-HNPPCas9 or P-HNPPCas9+sgPlk1 (n = 7). Black and red arrows indicate the injection day of P-HNPPCas9 or P-HNPs containing Plk1-targeting sgRNAs (P-HNPsgPlk1), respectively. The injection dose was 20 μg for PCas9 or sgPlk1. (D) Survival of HeLa xenograft mice in C. Euthanasia was performed when tumor volumes reached 1,000 mm3. (E) Expression level of Plk1 protein in tumor tissues in C, analyzed at 48 h post last injection.
Fig. 5. In vivo gene disruption and tumor growth suppression. (A) Indels of the Plk1 gene in HeLa cells treated with P-HNPs containing px165 only (P-HNPPCas9) or P-HNPs containing px165 and Plk1-targeting sgRNAs (P-HNPPCas9+sgPlk1). (B) Viability of HeLa cells at 72 h after transfection with P-HNPPCas9 or P-HNPPCas9+sgPlk1. Free, cells treated with free px165 and free Plk1-targeting sgRNAs; UT, untreated cells. (C) The inhibition of tumor growth in HeLa xenograft tumor-bearing mice after intratumoral injection of P-HNPPCas9 or P-HNPPCas9+sgPlk1 (n = 7). Black and red arrows indicate the injection day of P-HNPPCas9 or P-HNPs containing Plk1-targeting sgRNAs (P-HNPsgPlk1), respectively. The injection dose was 20 μg for PCas9 or sgPlk1. (D) Survival of HeLa xenograft mice in C. Euthanasia was performed when tumor volumes reached 1,000 mm3. (E) Expression level of Plk1 protein in tumor tissues in C, analyzed at 48 h post last injection.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

Sorted by citations

See all 277

Related

See all

Metadata

Authors
Wang, H.-X., Song, Z., Lao, Y.-H., Xu, X., Gong, J., Cheng, D., Chakraborty, S., Park, J. S., Li, M., Huang, D., Yin, L., Cheng, J., & Leong, K. W.
Affiliations
  • Department of Biomedical Engineering, Columbia University, New York, NY 10027;
  • University of Illinois Urbana-Champaign (US)
  • Columbia University (US)
  • Soochow University (CN)
  • Sun Yat-sen University (CN)
Corresponding author
  • Yin, Lichen
  • Cheng, Jianjun
  • Leong, Kam W.
ORCID
Venue
Proceedings of the National Academy of Sciences
Publisher
National Academy of Sciences
Published
2018-04-23
Volume
115
Issue
19
Pages
4903-4908
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
DOI
10.1073/pnas.1712963115
PMC
PMC5948953
OpenAlex
W2802061036
Cited by
277
References
34
Citations by year
2026: 9 · 2025: 18 · 2024: 21 · 2023: 41 · 2022: 47 · 2021: 41 · 2020: 43 · 2019: 42 · 2018: 15
FWCI
12.54
Type
journal article
Language
en
Open access
Licence
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Columbia Academic Commons (Columbia University)
Funders
  • National Natural Science Foundation of China (51573123, 51722305)
  • Ministry of Science and Technology of the People's Republic of China (2016YFA0201200)
  • Guangdong Innovative and Entrepreneurial Research Team Program (NO.2013S086)
  • Global Research Laboratory Program Korean NSF (2015032163)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
Keywords
CRISPR/Cas9 delivery, PEGylated nanoparticles, cell-penetrating peptides, endosomal escape, multiplex genome editing, PLK1, tumor growth inhibition, gene knock-in, gene activation
MeSH terms
Gene Editing, Animals, HeLa Cells, Humans, Plasmids, Gene Transfer Techniques, K562 Cells, NIH 3T3 Cells, Mice, Nanoparticles, HEK293 Cells, Cell-Penetrating Peptides, CRISPR-Cas Systems

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review